The makers of Yaz, Yasmin and Ocella have agreed to provide nearly $56.9 million to establish a settlement program for plaintiffs claiming they suffered arterial blood clots as a result of taking the birth-control drugs.
Bayer, which makes Yaz and Yasmin, and Barr Laboratories and Teva Pharmaceuticals, the makers of the generic drug Ocella, have agreed to provide $56.9 million to settle claims that the drospirenone-containing birth control drugs led to stroke and heart attacks. The agreement covers cases pending in Pennsylvania, California and New Jersey.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
